RIBASPHERE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RIBASPHERE (RIBASPHERE).
Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by competing with endogenous nucleotides and interfering with viral polymerase activity. It also has immunomodulatory effects.
| Metabolism | Hepatic metabolism via deribosylation and hydrolysis; not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal (80% unchanged, with remainder as metabolites); biliary/fecal (minor, <10%). |
| Half-life | Terminal elimination half-life: 40-60 hours in patients with normal renal function; prolonged in renal impairment (up to 100 hours). Accumulation occurs with repeated dosing. |
| Protein binding | 60-70% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 1.4-1.8 L/kg; indicates extensive tissue distribution, including liver. |
| Bioavailability | Oral bioavailability: 40-70% (increased with high-fat meal). |
| Onset of Action | Oral: 1-2 hours for serum concentration; clinical effect (antiviral) within days to weeks. |
| Duration of Action | Dosing interval is based on half-life; clinical effect persists for weeks after discontinuation. Used in combination with direct-acting antivirals. |
800-1200 mg/day orally in 2 divided doses for hepatitis C, in combination with peginterferon alfa or other direct-acting antivirals.
| Dosage form | CAPSULE |
| Renal impairment | Creatinine clearance 30-50 mL/min: reduce dose by 50%; <30 mL/min or hemodialysis: contraindicated. |
| Liver impairment | Child-Pugh class A: no adjustment; class B or C: contraindicated. |
| Pediatric use | Weight-based: 15 mg/kg/day orally in 2 divided doses for children ≥3 years with chronic hepatitis C. |
| Geriatric use | No specific adjustments; use caution due to age-related renal impairment and increased risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RIBASPHERE (RIBASPHERE).
| Breastfeeding | Ribavirin is excreted into human milk; the milk-to-plasma ratio is unknown. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during ribavirin therapy and for 6 months after the last dose. Women should be advised to discontinue nursing or not take the drug. |
| Teratogenic Risk | Ribavirin is contraindicated in pregnancy (FDA Category X). In animal studies, ribavirin has demonstrated significant teratogenic and embryocidal effects at doses well below the recommended human dose. For pregnant women with chronic hepatitis C, therapy with ribavirin is contraindicated. For male patients, ribavirin causes testicular toxicity and may induce sperm abnormalities; it is recommended that female partners of male patients avoid pregnancy during treatment and for 6 months after the last dose due to drug accumulation in sperm. |
■ FDA Black Box Warning
Hemolytic anemia, which may worsen cardiac disease and lead to myocardial infarction; monotherapy is not effective for chronic hepatitis C; must not be used alone.
| Serious Effects |
Pregnancy (female and male partners), hemoglobinopathies (e.g., thalassemia major, sickle cell anemia), autoimmune hepatitis, severe renal impairment (CrCl <50 mL/min), and known hypersensitivity to ribavirin.
| Precautions | Hemolytic anemia (requires dose reduction or discontinuation), teratogenicity (pregnancy category X), pancreatitis, pulmonary infiltrates, bone marrow suppression, ophthalmologic effects, thyroid abnormalities, and hypersensitivity reactions. |
Loading safety data…
| Fetal Monitoring | Pregnancy testing should be performed immediately before initiation of therapy, monthly during treatment, and for 6 months after discontinuation in all female patients of childbearing potential. Two reliable forms of effective contraception must be used during therapy and for 6 months post-treatment. Male patients with female partners of childbearing potential must also use condoms during therapy and for 6 months after treatment. If pregnancy occurs during therapy, the patient should be apprised of the potential hazard to the fetus. |
| Fertility Effects | Ribavirin causes reversible testicular toxicity in animal models, including decreased sperm counts and abnormal sperm morphology. In human males, ribavirin may impair spermatogenesis; sperm abnormalities have been reported. Effects on female fertility are not well characterized, but animal studies show reduced fertility. It is recommended that male patients use contraception during and for 6 months after treatment to avoid potential fetal exposure. |